Obsessive-Compulsive Disorder

Obsessive-compulsive disorder (OCD) is classified separately from the anxiety disorders in DSM-5-TR, alongside a family of related conditions that includes body dysmorphic disorder, hoarding disorder, trichotillomania (hair-pulling disorder), and excoriation (skin-picking) disorder.^[1] Obsessions are recurrent, intrusive thoughts, images, or urges that provoke marked anxiety and are difficult to suppress or ignore; compulsions are repetitive behaviours (washing, checking, ordering) or mental acts (counting, silently repeating a phrase) performed to neutralize the distress an obsession causes or to prevent a feared outcome, even though the connection between the compulsion and the feared outcome is often unrealistic. Mean age of onset is in the early twenties, with a substantial proportion of cases beginning in childhood or early adolescence; onset tends to be earlier in males, while the disorder overall is more common in females.^[2] In severe, inadequately treated OCD, rituals can occupy many hours of the day and become severely disabling — but the reverse is equally true: correctly dosed and adequately durated treatment produces real, durable symptom reduction for most patients, which makes getting the dose and duration right one of the highest-yield things a pharmacist can influence in this condition.

OCD presents along a small number of recognizable symptom themes, most patients experiencing more than one. Recognizing the theme helps distinguish OCD from superficially similar presentations (see the differential table in Assessment & Diagnosis) and helps a pharmacist understand why a patient's ritual makes internal sense to them even when it appears irrational to an outside observer.

Insight specifier

DSM-5-TR requires specifying the patient's insight into their OCD beliefs at the time of assessment: good or fair insight (recognizes the obsessive-compulsive beliefs are definitely or probably not true), poor insight (thinks the beliefs are probably true), or absent insight/delusional beliefs (completely convinced the beliefs are true). Insight can fluctuate over the course of the illness and does not by itself indicate a primary psychotic disorder — but very poor or absent insight changes the differential and the counselling approach (see Assessment & Diagnosis).^[1]

Tic-related specifier and pediatric-onset presentations

DSM-5-TR also specifies whether OCD is tic-related (a current or past history of a tic disorder), which is more common in males and in childhood-onset OCD. A distinct, more controversial pattern in children is pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS) — an abrupt, dramatic onset or exacerbation of OCD symptoms temporally linked to a streptococcal infection. Screen for a recent streptococcal infection when a child presents with an unusually sudden-onset OCD picture, though the entity remains debated in the literature.^[2]

• Family history of OCD or a related disorder (body dysmorphic disorder, hoarding disorder, tic disorder) in a first-degree relative.
• Personal or family history of a tic disorder, particularly for childhood-onset, tic-related OCD.
• Female sex (OCD is somewhat more common in females overall, though onset tends to occur earlier in males).
• Perinatal and postpartum period — new-onset or worsening OCD, particularly harm-related obsessions about the infant, is common in this window.
• Head injury or a neurocognitive disorder, which can rarely trigger obsessive-compulsive symptoms.
• New use of a stimulant, a dopamine agonist (e.g., pramipexole), or a serotonin-dopamine antagonist (e.g., clozapine) — screen medication history for these before assuming a primary psychiatric cause.
• Recent streptococcal infection in a child with abrupt-onset symptoms (possible PANDAS) — a debated but still relevant history question.
• Comorbid anxiety disorder, depression, or another OCD-spectrum condition.

Differentiating OCD from commonly confused presentations

History

• Nature and onset of obsessions and compulsions, and the extent of resulting distress, time consumed, and functional disability at work, school, and home.
• Related difficulties: symptom-related beliefs, avoidance behaviour, and family/partner accommodation (family members participating in or facilitating rituals to reduce the patient's distress) — accommodation maintains and can worsen symptoms and is an important target for CBT.
• Comorbid medical or psychiatric conditions. When comorbid depressive symptoms are present, distinguish a true comorbid mood disorder from secondary depression driven by OCD itself, which commonly remits spontaneously as OCD symptoms improve.^[2]
• Screen medication and substance history for triggers: new stimulant use, dopamine agonists (e.g., pramipexole), and serotonin-dopamine antagonists (e.g., clozapine) have all been associated with obsessive-compulsive symptoms.^[2]
• In children with abrupt-onset symptoms, ask about a recent streptococcal infection (possible PANDAS).

DSM-5-TR diagnostic criteria

• Presence of obsessions, compulsions, or both, as defined above.
• The obsessions/compulsions are time-consuming (commonly more than 1 hour per day) or cause clinically significant distress or impairment in social, occupational, or other important functioning.
• The symptoms are not attributable to a substance or another medical condition.
• The symptoms are not better explained by another mental disorder.

Insight (good/fair, poor, or absent/delusional) and tic-relatedness are recorded as specifiers, not separate diagnostic requirements — a patient with poor insight still has OCD, not a primary psychotic disorder, provided the presentation otherwise fits (see the differential table above).^[1]

Standardized severity measurement — Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

The Y-BOCS is the standard instrument for rating OCD severity and tracking treatment response.^[3] It is a clinician-administered, semi-structured interview, not a self-scored questionnaire — a trained rater first reviews a symptom checklist to identify the patient's specific obsessions and compulsions, then rates 10 items (5 on obsessions, 5 on compulsions: time occupied, interference, distress, resistance, and control) each from 0 (none) to 4 (extreme) against defined anchor descriptions, for a total score of 0-40.

Because scoring requires a trained rater applying clinical judgment to open-ended interview responses against anchor descriptions — not a fixed patient-completed point-sum like the GAD-7 or PHQ-9 — the Y-BOCS is not suitable for a self-serve interactive calculator on this page; use the table above only as an orientation to how severity is categorized, and use the validated instrument itself (or a brief validated alternative such as the 6-item Brief Obsessive Compulsive Scale) for actual clinical scoring.^[3]

When testing is not indicated

Routine neuroimaging, EEG, or laboratory testing is not indicated for a typical OCD presentation. Reserve investigation for signs pointing to an organic cause — a genuinely abrupt onset, an atypical age of onset, focal neurologic findings, or a temporal link to head injury, a new neurocognitive disorder, or a newly started dopaminergic/stimulant medication.

• Eliminate or substantially decrease obsessions and compulsions, aiming for full remission (Y-BOCS in or near the subclinical/mild range) rather than partial symptom reduction alone.
• Eliminate or reduce OCD-associated functional disability at work, school, and home, including reducing family/partner accommodation of rituals.
• Prevent relapse through an adequate duration of continued treatment.
• Restore overall quality of life.
• Identify and treat comorbid conditions (depression, another anxiety disorder, a related OCD-spectrum disorder) concurrently.

Specialized CBT with exposure and response prevention (ERP)

ERP — systematic, graded exposure to feared stimuli while the patient refrains from performing the associated compulsion — is the active ingredient of first-line OCD psychotherapy. "Specialized" CBT for OCD is meaningfully different from generic anxiety-disorder CBT: it uses subtype-specific protocols tailored to the patient's particular obsession-compulsion pattern (contamination/washing, harm/checking, symmetry, taboo-thought themes), and produces substantial, durable symptom reduction for most patients who complete a course.^[2] Many patients do not respond adequately to standard weekly in-office sessions alone and need increased session frequency/duration or therapist-assisted protocols delivered in the patient's own environment; centres offering subtype-specific, non-time-limited, therapist-assisted specialty protocols report the best outcomes. Where this level of expertise is not locally available, refer to or arrange consultation with a clinician with specific OCD/ERP expertise rather than substituting generic anxiety-focused CBT.

Internet-delivered CBT is a promising option for improving access where in-person specialized CBT is unavailable and merits continued study, but is not a substitute for specialized, therapist-directed ERP when that option is accessible.

Patients with prominent metacognitive dysfunction (strong symptom-related beliefs), overvalued ideas, or very high distress/intolerance of distress may not respond to ERP alone and can require additional specialized cognitive therapy techniques layered onto ERP.^[2]

Family/partner accommodation

Identify and address family or partner participation in rituals (providing reassurance on demand, performing checking behaviours for the patient, altering household routines to avoid triggering obsessions) — accommodation is a common, correctable factor that maintains and can worsen OCD symptoms, and reducing it is a standard target woven into specialized CBT, particularly in pediatric treatment.^[8]

OCD-related disorders have their own specialized protocols

Hoarding disorder and body dysmorphic disorder each have their own disorder-specific CBT protocols, distinct from standard OCD-focused ERP (see Special Populations).^[2]

Not effective / reserved for refractory illness

Electroconvulsive therapy is not effective for OCD itself and is reserved for patients with a severe comorbid mood disorder. Brain stimulation (repetitive or deep transcranial magnetic stimulation) and, rarely, deep brain stimulation or neuroablative neurosurgery are reserved for patients who have not benefited from at least one full, adequately delivered trial of specialized CBT plus pharmacotherapy — see Treatment Failure & Next Steps.

Pregnancy

OCD symptoms, particularly harm-related obsessions about the baby, commonly worsen in pregnancy and can be extremely distressing; patients with these obsessions are not at higher risk of actually harming their child than the general population, but the distress and associated guilt/depression are real and often unvoiced unless directly asked about. Screen for OCD before conception where possible, and repeat screening during pregnancy and especially postpartum.^[2] Specialized CBT/ERP can be delivered throughout pregnancy and is preferred first-line where accessible. If symptoms are severe and functionally impairing, SSRI pharmacotherapy is appropriate — apply the same general principles used for depression in pregnancy (see Depression's Special Populations for the shared pregnancy risk-benefit framework); paroxetine carries higher associated risk than other SSRIs and should generally be avoided as a new start in pregnancy.^[2]

Breastfeeding

Nonpharmacologic treatment is preferred first-line in the postpartum period wherever possible. If drug therapy is needed, escitalopram and sertraline are preferred, given minimal transfer into breast milk.^[2] A patient with severe postpartum OCD can become so distressed by harm-related obsessions that she refuses to care for or be alone with the infant — this needs urgent psychiatric consultation (see Red Flags & Refer), not reassurance alone.

Children and adolescents

SSRIs are first-line pharmacotherapy for pediatric OCD, generally combined with specialized CBT/ERP adapted for the child's developmental level and involving the family directly (including active work on reducing family accommodation of rituals).^[8] Titrate more conservatively than in adults — modest dose increases roughly every 3 weeks rather than weekly — and monitor closely for behavioural activation (agitation, disinhibition, increased impulsivity), which is more common in younger children and can be a late-onset adverse effect that emerges as anxiety decreases; if activation is not manageable with a dose adjustment, rotate to a different SSRI rather than pushing through it.^[8] All antidepressants carry the same boxed warning regarding increased suicidality risk under age 25 discussed in Red Flags & Refer, and this applies with particular relevance to pediatric OCD given how commonly it is treated in this age group. Continue an effective medication for 6-12 months after stabilization before considering a gradual taper.^[8] Fluvoxamine, fluoxetine, and sertraline have the most robust pediatric OCD evidence base; use adult titration principles adapted to lower starting doses and slower increases, with specialist input for dosing outside these three agents.

Older adults

Start SSRIs at a lower dose with slower titration than in a younger adult. Apply the citalopram/escitalopram QTc-prolongation caution with particular care in this age group, given a higher baseline prevalence of cardiac risk factors and polypharmacy. Clomipramine's anticholinergic and cardiovascular burden makes it a poor choice in most older patients — favour an SSRI or, for augmentation, aripiprazole/risperidone with close monitoring for orthostatic hypotension and falls risk.

Renal and hepatic impairment

Dose reduction may be needed for hepatically metabolized agents (most SSRIs, clomipramine) in significant hepatic impairment — start low and titrate slowly. No specific renal dose adjustment is required for most SSRIs at usual doses, but use caution with any agent in significant renal impairment given reduced overall clearance reserve; memantine's clearance can theoretically be reduced by urinary alkalizers (e.g., carbonic anhydrase inhibitors).

Track response with the Y-BOCS (or a brief validated alternative such as the 6-item Brief Obsessive Compulsive Scale) at the 4-week, 12-week, and other key clinical decision points rather than relying on unstructured impression alone.^[2] Reassess specifically at week 4: minimal improvement at this point makes a strong full response by 12 weeks substantially less likely, but does not by itself justify stopping early — continue the planned full-duration trial at the maximum tolerated dose unless adverse effects require a change, since meaningful further gains commonly continue to accrue between weeks 6 and 12.^[11][2] If augmentation is added, reassess its specific contribution at 4 weeks.

If treatment is successful, continue for at least 1 year before considering any dose reduction — relapse rates after early discontinuation are high, and this applies to medication monotherapy in particular.^[2] Wait for a period of sustained psychosocial stability before attempting discontinuation, individualize the decision to continue long-term therapy, and taper any antidepressant gradually rather than stopping abruptly, warning the patient to report early signs of relapse during the taper. After a course of specialized CBT/ERP, some patients can maintain stability after a carefully monitored SRI taper — this is a reasonable goal to discuss once ERP has been completed, not a default assumption for every patient.^[2]

At every follow-up, monitor for ongoing suicidal ideation (especially in patients under 25 and at any dose change), adherence, and — specifically for the antipsychotic augmentation agents — weight, metabolic parameters, and extrapyramidal symptoms. A community pharmacist is well positioned to catch the two most common, entirely preventable causes of apparent treatment failure: a patient who never reached an adequate dose, and a patient who stopped a trial well before the 8-12 week mark because early benefit felt underwhelming.

1. Distinguish technical treatment failure from actual treatment failure before doing anything else. Technical failure means the treatment was never adequately delivered — inadequate dose, inadequate duration (less than 8-12 weeks at the maximum tolerated dose), poor adherence, or ERP that was not truly specialized/subtype-specific. Actual treatment failure means a genuinely adequate trial still did not produce meaningful improvement. The two require completely different next steps, and technical failure is far more common — confirm dose, duration, and adherence explicitly before concluding a drug or a course of therapy "didn't work."^[5][12]
2. If the SSRI trial was adequate in dose but the duration fell short of 12 weeks, extend it rather than switching — meaningful improvement can still emerge between weeks 6 and 12.
3. Partial response at the maximum tolerated SSRI dose: augment with a low-dose second-generation antipsychotic (aripiprazole or risperidone) rather than switching to a second SRI monotherapy trial.^[7][13]
4. No meaningful response despite a confirmed adequate trial: switch to a different SSRI, or to clomipramine.
5. If the second SRI trial also fails: augment with aripiprazole or risperidone rather than attempting a third sequential SRI monotherapy trial.
6. If antipsychotic augmentation is not tolerated or is ineffective after an adequate trial (assessed at 4 weeks): try a glutamate-modulating agent (lamotrigine or memantine first; topiramate or amantadine as further options).
7. At every step, confirm specialized CBT/ERP has genuinely been tried (not generic anxiety-focused CBT, and not low-intensity self-help) — if it has not, arranging it is often the single highest-yield next step regardless of which medication track the patient is on.
8. After exhausting an adequate trial of specialized CBT/ERP plus at least 1 adequate SRI trial with antipsychotic augmentation, refer to psychiatry for consideration of glutamate-modulating agents under specialist direction, or brain stimulation (repetitive/deep transcranial magnetic stimulation) — these are reserved specifically for patients who have not benefited from at least 1 optimal trial each of specialized CBT and pharmacotherapy. Deep brain stimulation and neuroablative neurosurgery are last-resort options for the most severely refractory patients, undertaken only after independent expert consultation.

• Declaring an SSRI trial a failure before 8-12 weeks at the maximum tolerated dose — the single most common, entirely avoidable cause of apparent "SSRI failure" in OCD is a trial that was simply never adequate in dose or duration, not a genuine non-response.^[12]
• Using the depression trial-duration rule (4-6 weeks) for OCD instead of the correct, longer 8-12 week rule.
• Stopping dose escalation at the standard depression/anxiety target dose instead of continuing to the OCD-specific maximum tolerated dose.
• Switching to a new SRI after only a partial response instead of augmenting — and, conversely, augmenting after a genuine zero response instead of switching first.
• Attempting a third sequential SRI monotherapy trial instead of moving to antipsychotic augmentation after 2 adequate SRI trials have failed.
• Recommending low-intensity self-help CBT or a stepped-care approach as a substitute for specialized, subtype-specific CBT/ERP — this is not evidence-based for OCD and risks avoidable undertreatment.
• Treating medication and ERP as competing options rather than combining them whenever possible — combination meaningfully outperforms either alone.
• Using benzodiazepines or lithium as OCD monotherapy — neither is effective for core OCD symptoms; reserve them for a specific comorbid indication (e.g., severe comorbid anxiety or a mood disorder).
• Missing a reversible medication or substance trigger (a new stimulant, dopamine agonist, or serotonin-dopamine antagonist) in a patient with new-onset obsessive-compulsive symptoms.
• Treating body dysmorphic disorder at standard depression-range SSRI doses instead of the higher, OCD-range doses it actually requires.
• Missing severe hoarding as a home-safety issue because it was framed only as a psychiatric symptom rather than also flagged for practical safety triage.
• Not screening explicitly for suicidal ideation at SSRI initiation and at every dose change, particularly in patients under 25.
• Stopping an SSRI or clomipramine abruptly instead of tapering gradually.

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment — see Special Populations for pediatric, pregnancy/breastfeeding, and older-adult dosing considerations. Select any drug name to open its complete Pharmasist Drug Database page.

Selective serotonin reuptake inhibitors (SSRIs) — 1st line

All 6 agents are considered comparably effective for OCD; selection is guided by tolerability and interaction profile, not superior efficacy of one over another. OCD requires notably higher target doses and a longer (8-12 week) trial at the maximum tolerated dose than depression or generalized anxiety before a trial can be judged to have failed.

Tricyclic antidepressant — 2nd-line monotherapy

Clomipramine is similarly effective to SSRIs in head-to-head evidence, but its adverse-effect burden and overdose lethality make it a reserved, not first, choice.

SNRI and NaSSA — 2nd-line monotherapy

Reasonable options after SSRI failure or intolerance, though generally regarded as somewhat less preferred than a genuine switch to a second SSRI.

Dopamine receptor antagonist/partial agonist augmentation — 1st-line augmentation for partial SSRI response

Titrate to the middle of the standard antipsychotic dosing range — higher than typical augmentation doses used in major depressive disorder. Reassess efficacy specifically at 4 weeks; weigh metabolic and movement-disorder adverse effects against benefit at every review, and do not continue indefinitely without reassessment.

Glutamate-modulating agents — 2nd/3rd-line augmentation after antipsychotic augmentation fails or is not tolerated

Preliminary evidence supports these agents added to an SSRI in refractory OCD. Lamotrigine and memantine are generally the best-tolerated of the group and are reasonable next options; topiramate has poorer tolerability but is a reasonable choice with comorbid migraine, binge-eating pattern, or antipsychotic-associated weight gain.